16,335 results match your criteria Psoriatic Arthritis


Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls.

Clin Rheumatol 2018 Dec 7. Epub 2018 Dec 7.

Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.

Objectives: The mean age at onset of psoriatic arthritis (PsA) ranges between the 4th-6th decades of life. However, little is known about fertility and pregnancy outcome in PsA patients. The aim of this study was to examine whether fertility and pregnancy outcome of PsA patients are different from healthy controls and to evaluate PsA and psoriasis disease activity perception during pregnancy and the year postpartum. Read More

View Article
December 2018

Preliminary validation of the Simplified Psoriatic Arthritis Radiographic Score (SPARS).

Skeletal Radiol 2018 Dec 7. Epub 2018 Dec 7.

Radiology Department, Università Politecnica delle Marche, Ancona, Italy.

Objective: To develop and validate in a preliminary way a novel radiographic scoring system for psoriatic arthritis (PsA), called Simplified Psoriatic Arthritis Radiographic Score (SPARS).

Materials And Methods: Radiographs of hands and feet were obtained from consecutive PsA patients and assessed by two readers. For each joint (30 joints in the hands, ten joints in the feet), the combination of the erosions, joint narrowing space (JNS) and bony proliferation (BP) has been assessed, giving a value of 1 for erosions presence, 1 for JNS presence, and 1 for BP presence (SPARS score range, 0-120). Read More

View Article
December 2018

To what extend is nail ultrasound discriminative between psoriasis, psoriatic arthritis and healthy subjects?

Rheumatol Int 2018 Dec 10. Epub 2018 Dec 10.

Department of Social Psychology and Methodology, Facultad de Psicología, Universidad Autónoma de Madrid, Madrid, Spain.

To assess the discriminative utility of nail features detected by B-mode (BM) and color Doppler (CD) ultrasound (US) between patients with psoriasis (PsO) and psoriatic arthritis (PsA) and healthy controls. Sixty patients with PsA, 21 patients with PsO, and 20 healthy controls were prospectively included. All patients underwent a dermatologic assessment and PsA patients also a rheumatologic assessment. Read More

View Article
December 2018

Delayed Diagnosis of Psoriatic Arthritis Mutilans due to Arthritis Prior to Skin Lesion.

Case Rep Rheumatol 2018 4;2018:4216938. Epub 2018 Nov 4.

Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.

Psoriatic arthritis (PsA) is a type of inflammatory arthritis characterized by cutaneous psoriasis, peripheral joint damage, axial joint damage, and enthesitis and is usually diagnosed after the appearance of psoriatic skin disease. PsA mutilans is relatively rare in Japan. In the present case, the patient was diagnosed with PsA with foot mutilans deformity only. Read More

View Article
November 2018

The IL-1 pathway is hyperactive in Hidradenitis suppurativa and contributes to skin infiltration and destruction.

J Invest Dermatol 2018 Dec 5. Epub 2018 Dec 5.

Interdisciplinary group Molecular Immunopathology, Dermatology / Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Psoriasis Research and Treatment Center, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address:

Hidradenitis suppurativa (HS; also designated as acne inversa) is a chronic inflammatory disease characterized by painful purulent skin lesions and progressive destruction of skin architecture. Despite the high burden for the patients, pathogenetic pathways underlying HS alterations remain obscure. Investigating the lesional HS cytokine pattern, IL-1β turned out as a highly prominent cytokine, being overexpressed even compared to psoriatic lesions. Read More

View Article
December 2018

Neutrophil Extracellular Traps Induce Human Th17 Cells: Effect of Psoriasis-Associated TRAF3IP2 Genotype.

J Invest Dermatol 2018 Dec 5. Epub 2018 Dec 5.

Dermatology, University of Michigan, Ann Arbor, MI, United States; Ann Arbor Veterans Affairs Hospital, Ann Arbor, MI, United States. Electronic address:

Psoriasis lesions are rich in IL-17-producing T-cells as well as neutrophils, which release webs of DNA-protein complexes known as neutrophil extracellular traps (NETs). Because we and others have observed increased NETosis in psoriatic lesions, we hypothesized that NETs contribute to increased Th17 cells in psoriasis. After stimulating peripheral blood mononuclear cells (PBMCs) with anti-CD3/CD28 beads for 7 days, we found significantly higher percentages of CD3+CD4+IL-17+ (Th17) cells in the presence vs. Read More

View Article
December 2018

Smoking, but not alcohol, is associated with risk of psoriasis in a Taiwanese population-based cohort study.

J Am Acad Dermatol 2018 Dec 7. Epub 2018 Dec 7.

Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Public Health and Department of Public Health, National Yang-Ming University, Taipei, Taiwan. Electronic address:

Background: Alcohol consumption and smoking have long been suspected of increasing the risk of developing psoriasis. Most evidence to date has derived from cross-sectional or case-control studies.

Objective: We sought to investigate the effects of alcohol and smoking on incident psoriasis. Read More

View Article
December 2018

Increased risk of incident thyroid diseases in people with psoriatic disease: A cohort study.

J Am Acad Dermatol 2018 Dec 5. Epub 2018 Dec 5.

Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address:

Background: The association between psoriasis and thyroid diseases was unclear.

Objective: To examine the risk of thyroid diseases in psoriasis patients.

Methods: We used Taiwan's National Health Insurance Research Database to conduct a nationwide cohort study. Read More

View Article
December 2018
1 Read

Update on the epidemiology, risk factors, and disease outcomes of psoriatic arthritis.

Best Pract Res Clin Rheumatol 2018 04 5;32(2):295-311. Epub 2018 Oct 5.

Division of Rheumatology, University of Ottawa, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, Canada; The Ottawa Hospital Research Institute, University of Ottawa, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, Canada. Electronic address:

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects different structures of the musculoskeletal system in addition to the skin and the nail. The complexity of the disease had been a barrier to understand the pathogenesis and define valid outcome tools; however, our understanding about the disease has considerably increased with time mainly because of the advances in imaging, new discoveries in genetics and underlying inflammatory pathways, and better understanding of the epidemiology of the disease and environmental risk factors. The purpose of this review is to summarize developments and changes in epidemiology, risk factors for developing PsA, and outcome measures with a focus on data obtained in the last 10 years. Read More

View Article

TRPV1 mediates inflammation and hyperplasia in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) in mice.

J Dermatol Sci 2018 Nov 26. Epub 2018 Nov 26.

Department of Dermatology, University of California, Davis, CA, USA. Electronic address:

Background: Transient Receptor Potential Vanilloid 1 (TRPV1) is known to mediate itch and neurogenic inflammation, but the role of TRPV1 in psoriasiform dermal inflammation is poorly understood.

Objective: To investigate the function of TRPV1 in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) in mice.

Methods: Following daily treatment of topical IMQ cream for consecutive 5 days in C57BL/6 wide-type (WT) and TRPV1 gene knockout (KO) mice, we assessed the psoriasis severity index (PSI) scores, transepidermal water loss (TEWL), dermal inflammatory infiltrates, as well as gene expression levels for psoriasis related genes in mouse skin lesions. Read More

View Article
November 2018

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Arthritis Res Ther 2018 Dec 7;20(1):272. Epub 2018 Dec 7.

Novartis Pharma AG, Basel, Switzerland.

Background: Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessed the ability of secukinumab to achieve Psoriatic Arthritis Disease Activity Score (PASDAS)-based remission or low disease activity (LDA) through 2 years among patients with PsA in the FUTURE 2 study.

Methods: PASDAS (cut-off scores: remission ≤ 1. Read More

View Article
December 2018

Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice.

J Dermatolog Treat 2018 Dec 8:1-4. Epub 2018 Dec 8.

a Dermatology Unit, Department of Clinical and Translational Medicine , University of Pisa , Pisa , Italy.

View Article
December 2018

Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.

Acta Derm Venereol 2018 Dec 6. Epub 2018 Dec 6.

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 1, IT-40138 Bologna, Italy.

Nail psoriasis affects 50-79% of patients with skin psoriasis and up to 80% of patients with psoriatic arthritis, and can also represent a negative prognostic factor in individuals with plaque psoriasis. Treatments for nail psoriasis are limited, as nails are often difficult to treat with topical therapies alone, and relapse is common. Among different systemic agents, secukinumab, a fully human monoclonal antibody targeting interleukin (IL)-17A, is the only antibody supported by a trial specifically conducted in patients with nail psoriasis (the TRANSFIGURE trial) and has the longest follow-up available to date. Read More

View Article
December 2018
3 Reads

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.

Psoriasis (Auckl) 2018 13;8:83-92. Epub 2018 Nov 13.

Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal,

Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients' quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab), and most recently IL-17 inhibitors. Risankizumab is a monoclonal antibody which targets IL-23p19 without binding IL-12. Read More

View Article
November 2018
1 Read

Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies.

Biologics 2018 12;12:151-158. Epub 2018 Nov 12.

Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

Objectives: To describe the therapeutic pathways of patients with psoriasis (PSO) and psoriatic arthritis (PsA) before and after treatment with biological therapies in a real-world setting and to determine the relative consumption of health care resources.

Design: Retrospective observational study.

Setting: Real-life clinical setting in 5 Italian local health units. Read More

View Article
November 2018

A Drug with Lipophilicity-Dependent Potency Can Be Metabolically Stable: Discovery of a Potent and Selective Retinoic Acid Receptor-Related Orphan Receptor C2 (RORC2) Inverse Agonist as an Orally Bioavailable Anti-Inflammatory Agent.

J Med Chem 2018 Dec 3. Epub 2018 Dec 3.

State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China.

IL-17 drives an amplification mechanism in inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The production of IL-17 depends on the activity of RORC2 in immune cells, which suggests that RORC2 inverse agonists are capable of anti-inflammatory therapy by reducing IL-17 levels. However, oral delivery of inverse agonists remains a challenge since the binding pocket of RORC2 prefers to accommodate lipophilic ligands, which tend to have poor metabolic stability. Read More

View Article
December 2018

Expression of Vascular Endothelial Growth Factor and Microvessel Density in Psoriatic Skin Lesions.

Indian Dermatol Online J 2018 Nov-Dec;9(6):418-421

Department of Dermatology, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, Karnataka, India.

Background: Psoriasis is a common chronic and immune-mediated skin disorder having a significant impact on the patient's quality of life. An analysis of the role of angiogenic vascular endothelial growth factor (VEGF) expression and microvessel density in psoriatic skin lesions may help in better understanding of the disease pathogenesis. The aim of this study was to examine the expression of vascular endothelial growth factor (VEGF) and microvessel density using CD34 antibodies in psoriatic skin lesions by immunohistochemical examination using normal skin of healthy individuals as controls. Read More

View Article
December 2018
2 Reads

Sleep disorders in patients with psoriatic arthritis and psoriasis.

Reumatologia 2018 31;56(5):301-306. Epub 2018 Oct 31.

Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Poland.

Objectives: To assess and measure occurrence of sleep disorders in patients with psoriatic arthritis (PsA) and psoriasis (Ps).

Material And Methods: The study included 62 patients with psoriatic arthritis and 52 patients with psoriasis. The measurement of sleep quality was conducted using the Pittsburgh Sleep Quality Index (PSQI), the evaluation of fatigue by the fatigue subscale of the FACIT-F questionnaire and the patient's quality of life by the Health Assessment Questionnaire (HAQ). Read More

View Article
October 2018

A Case of Ostraceous Psoriasis with Psoriatic Arthritis in an AIDS Patient.

Indian J Dermatol 2018 Nov-Dec;63(6):512-514

Department of Dermatology, College of Medicine, Dankook University, Cheonan, Korea.

Human immunodeficiency virus (HIV) infection may present with severe and atypical cutaneous diseases. Psoriasis also can develop in HIV patients associated with immune dysfunction and be presented as more severe and atypical manifestation. Furthermore, treatment of psoriasis in HIV patients can be complex and challenging. Read More

View Article
December 2018

What Is Axial Psoriatic Arthritis?

J Rheumatol 2018 Dec;45(12):1611-1613

Krembil Research Institute, Toronto Western Hospital, University Health Network; Division of Rheumatology, Department of Medicine, and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

View Article
December 2018

Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content.

Rheumatology (Oxford) 2018 Dec 4. Epub 2018 Dec 4.

Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology and Immunology Center.

Objectives: Synovial mast cells contain IL-17A, a key driver of tissue inflammation in SpA. A recent in vitro study showed that tissue-derived mast cells can capture and release exogenous IL-17A. The present study aimed to investigate if this mechanism could contribute to tissue inflammation in SpA. Read More

View Article
December 2018
1 Read

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.

Rheumatology (Oxford) 2018 Dec 4. Epub 2018 Dec 4.

Medical Affairs, Janssen Inc., Toronto, ON, Canada.

Objectives: Treat to target recommendations for PsA state that the target of treatment should be remission or, at the very least, low disease activity. Different clinical indexes have been proposed to define these disease states including the minimal disease activity criteria and the Disease Activity Index for PsA (DAPSA) scores, which have 7 and 4-5 domains, respectively. Using a Canadian cohort, the objectives were to calculate the proportion of patients achieving these criteria, their prognostic value and the overall patient impact of these disease states. Read More

View Article
December 2018
2 Reads

Stat3 activation in epidermal keratinocytes induces Langerhans cell activation to form an essential circuit for psoriasis via IL-23 production.

J Dermatol Sci 2018 Nov 23. Epub 2018 Nov 23.

Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.

Background: Psoriasis is an inflammatory disease associated with aberrant crosstalk between the epidermis and immune system. However, the role of Langerhans cells (LCs) in psoriasis remains controversial.

Objectives: To elucidate whether LCs are functionally involved in the development of psoriasis using a mouse model. Read More

View Article
November 2018

Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors.

J Clin Med 2018 Dec 1;7(12). Epub 2018 Dec 1.

Rheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy.

The prevalence of sarcopenia in rheumatic diseases has been evaluated in single diseases using various diagnostic approaches, generating conflicting data on the pathogenetic mechanism(s). Herein, we evaluated both muscle mass index (MMI) and muscle strength to assess sarcopenia and presarcopenia in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Moreover, we evaluated the possible impact of disease/patient-related characteristics, therapeutic regimens, and nutritional aspects on sarcopenia. Read More

View Article
December 2018

PSORI-CM02 alleviates IMQ-induced mouse dermatitis via differentially regulating pro- and anti-inflammatory cytokines targeting of Th2 specific transcript factor GATA3.

Biomed Pharmacother 2018 Dec 1;110:265-274. Epub 2018 Dec 1.

Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China; Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China. Electronic address:

The IL-17-producing CD4+ T cell and γδT cells play critical roles in the pathogenesis of psoriasis (PS). PSORI-CM02 is a representative herbal formula for the treatment for PS in South China. It was confirmed to improve PS without obvious side effects in the clinic. Read More

View Article
December 2018
2 Reads

Treating psoriatic arthritis to target: discordance between physicians and patients' assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort.

Clin Rheumatol 2018 Dec 3. Epub 2018 Dec 3.

Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos 2350, Porto Alegre, CEP 90035-903, Brazil.

The treat-to-target strategy (T2T) was associated with better outcomes in psoriatic arthritis (PsA) compared to standard care in clinical trials. This study aimed to analyze factors precluding treatment optimization in a T2T strategy conducted in a real-world cohort of PsA patients. A retrospective cross-sectional study nested in a cohort was conducted. Read More

View Article
December 2018

Toll-Like Receptor 7 Agonist-Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells.

Cell Mol Gastroenterol Hepatol 2019 25;7(1):135-156. Epub 2018 Sep 25.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; Japan Agency for Medical Research and Development, AMED, Tokyo, Japan. Electronic address:

Background & Aims: Psoriasis and inflammatory bowel disease (IBD) are both chronic inflammatory diseases occurring in the skin and gut, respectively. It is well established that psoriasis and IBD have high concordance rates, and similar changes in immune cells and microbiome composition have been reported in both conditions. To study this connection, we used a combination murine model of psoriatic dermatitis and colitis in which mice were treated topically with the Toll-like receptor 7 agonist imiquimod (IMQ) and fed dextran sulfate sodium (DSS). Read More

View Article
September 2018
1 Read

Born to run: The paradox of biomechanical force in spondyloarthritis from an evolutionary perspective.

Best Pract Res Clin Rheumatol 2017 12 1;31(6):887-894. Epub 2018 Sep 1.

Department of Rheumatology - MRB2, Ghent University Hospital, Corneel Heymanslaan 10, BE-9000, Ghent, Belgium; VIB Center for Inflammation Research, Ghent University, Ghent, Belgium. Electronic address:

Spondyloarthritis (SpA) refers to a group of chronic inflammatory arthritic diseases that can be severely debilitating. The most common form of SpA affecting the peripheral skeleton is psoriatic arthritis, while that affecting the axial skeleton is ankylosing spondylitis. SpA has a multifactorial nature, with both genetic and environmental factors initiating and maintaining the disease. Read More

View Article
December 2017

Gut inflammation in spondyloarthritis.

Best Pract Res Clin Rheumatol 2017 12 27;31(6):863-876. Epub 2018 Sep 27.

Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Piazza delle Cliniche 2, 90127, Palermo, Italy. Electronic address:

Spondyloarthritis (SpA) is a group of related diseases sharing common etiopathogenic mechanisms and clinical manifestations supported by a complex genetic predisposition. Gut inflammation is present in patients with SpA including patients showing clinically evident intestinal inflammation in the form of Crohn's disease or ulcerative colitis and patients who despite the absence of signs and symptoms of intestinal inflammation display a subclinical gut inflammation. Emerging evidence suggests that subclinical gut inflammation in patients with SpA, apparently driven by intestinal dysbiosis, is not the consequence of the systemic inflammatory process but rather an important pathophysiological event actively participating in the pathogenesis of the disease. Read More

View Article
December 2017

Uveitis and spondyloarthropathies.

Best Pract Res Clin Rheumatol 2017 12 25;31(6):846-862. Epub 2018 Oct 25.

Oxford Eye Hospital, John Radcliffe Hospital, Headley Way, Oxford, United Kingdom. Electronic address:

Uveitis is a frequently occurring extra-articular manifestation of spondyloarthropathies (SpAs), ankylosing spondylitis (AS), reactive arthritis (ReA), psoriatic arthritis (PsA) and inflammatory bowel disease (IBD), occurring in both adults and children with SpA. Uveitis occurs with varying frequency according to the SpA subtype (33% in AS, 6-9% in PsA, 25% in ReA, 13% in undifferentiated SpA and 2-5% in IBD), the presence of HLA-B27 and with increasing duration of disease. The majority of cases of uveitis in SpA are attributed to acute anterior uveitis but a minority of uveitis cases occur in the posterior segment of the eye. Read More

View Article
December 2017

Anti-IL17 therapies for psoriasis.

Expert Opin Biol Ther 2018 Nov 30. Epub 2018 Nov 30.

a Division of Dermatology , Baylor Scott and White - Dallas , Dallas , TX , USA.

Introduction: Interleukin-17 (IL-17) is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of plaque psoriasis. As a result, focus in clinical trials has undergone a shift towards disease specific targets, with the goals of more effective treatment and reduction in the incidence of serious adverse events. Areas Covered: Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one against the IL-17 receptor (brodalumab) are approved for the treatment of moderate-to-severe plaque psoriasis. Read More

View Article
November 2018
4 Reads

Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.

Curr Rheumatol Rev 2018 Nov 29. Epub 2018 Nov 29.

Department of Rheumatology , Covina Arthritis Clinic, Covina, CA. United States.

Psoriasis is a chronic immune-mediated inflammatory dermatologic condition that is often associated with psoriatic arthritis. There are multiple regimens for the treatment of psoriasis including disease modifying anti rheumatics drugs, biologic agents, phototherapy, topical retinoid and steroids creams, as well as apremilast. Apremilast is an oral phosphodiesterase inhibitor that was approved by the FDA in March 2014 for the treatment of psoriatic arthritis and September 2014 for the treatment of moderate to severe plaque psoriasis. Read More

View Article
November 2018
2 Reads

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Arthritis Care Res (Hoboken) 2018 Nov 30. Epub 2018 Nov 30.

ECRI Institute, Plymouth Meeting, Pennsylvania.

Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).

Methods: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. Read More

View Article
November 2018
7 Reads

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Arthritis Rheumatol 2018 Nov 30. Epub 2018 Nov 30.

ECRI Institute, Plymouth Meeting, Pennsylvania.

Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).

Methods: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. Read More

View Article
November 2018
3 Reads

Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage.

Clin Rheumatol 2018 Nov 29. Epub 2018 Nov 29.

Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

Objective: Assessment of spinal lateral flexion (SLF) is important in spondyloarthritis (SpA). The INSPIRE method of measuring SLF requires one set of measurements, is faster, feasible, and correlates with the mSASSS in ankylosing spondylitis. The present study aimed to compare the INSPIRE to Domjan method in PsA patients and correlate with radiographic changes. Read More

View Article
November 2018
3 Reads

DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs.

RMD Open 2018 5;4(2):e000765. Epub 2018 Nov 5.

Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

Objectives: Disease Activity index for PSoriatic Arthritis (DAPSA) (sum score 68/66 tender/swollen joint counts (68TJC/66SJC), patient's global assessment, pain and C-reactive protein (CRP)) is recommended for clinical assessment of disease activity in patients with psoriatic arthritis (PsA). Ultrasound (US) (grey scale (GS) and power Doppler (PD)) detects inflammation in joints and extra-articular structures. The present objectives were to explore the longitudinal relationships between DAPSA, clinical assessment as well as patient-reported outcome measures (PROMs) with US in patients with PsA initiating biological DMARDs and the associations between DAPSA and US remission. Read More

View Article
November 2018
2 Reads

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB: possible fallout on non-medical switching.

Ann Rheum Dis 2018 Nov 28. Epub 2018 Nov 28.

Rheumatology Clinic, Azienda USL Toscana Centro, Nuovo S Giovanni di Dio Hospital, Florence, Italy.

View Article
November 2018

Evaluation of the occurrence of sexual dysfunction and general quality of life in female patients with psoriasis.

An Bras Dermatol 2018 Nov/Dec;93(6):801-806

Initial Rheumatoid Arthritis Outpatient Clinic, Hospital Universitário de Brasília, Universidade de Brasília, Brasília (DF), Brazil.

Background: Psoriasis has a significant impact on quality of life (QoL). Sexual life can also be affected, with sexual dysfunction being reported by 25-70% of patients.

Objectives: To determine the occurrence of sexual dysfunction and evaluate QoL in women with psoriasis. Read More

View Article
August 2013
1 Read

The role of PI3K/AKT/FOXO signaling in psoriasis.

Arch Dermatol Res 2018 Nov 27. Epub 2018 Nov 27.

Department of Dermatology, China-Japan Friendship Hospital, Beijing, 100029, China.

Phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT) signaling pathway play a central role in multiple cellular functions such as cell proliferation and survival. The forkhead box O (FOXO) transcription factors are negatively regulated by the PI3K/AKT signaling pathway and considered to have inhibitory effect on cell proliferation. Psoriasis is a multifactorial disease with a strong genetic background and characterized by hyperproliferative keratinocyte. Read More

View Article
November 2018

Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy.

J Dermatolog Treat 2018 Nov 28:1-4. Epub 2018 Nov 28.

b Department of Dermatology, Venereology and Andrology , Aswan University , Aswan , Egypt.

Background: Psoriasis is a common chronic and immune-mediated inflammatory skin disease.

Objectives: This study aimed to investigate the serum levels of Chitinase-3-like protein 1 (YKL-40) in patients with psoriasis vulgaris before and after narrow-band ultraviolet B (NB-UVB) phototherapy.

Methods: This study was designed as a cross-sectional case-control. Read More

View Article
November 2018
2 Reads

Membrane-enriched solute carrier family 2 member 1 (SLC2A1/GLUT1) in psoriatic keratinocytes confers sensitivity to 2-deoxy-D-glucose (2-DG) treatment.

Exp Dermatol 2018 Nov 27. Epub 2018 Nov 27.

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.

Psoriasis is a common chronic disease with accelerated epidermal cell growth. Solute carrier family 2 member 1 (SLC2A1), also named GLUT1, transports glucose and its analogues into cells. With elevated membrane-bound GLUT1, psoriatic keratinocytes uptake more glucose with increased glucose metabolism. Read More

View Article
November 2018
2 Reads

Chronic recurrent multifocal osteomyelitis with psoriatic skin manifestations in a 12-year-old female.

Dermatol Pract Concept 2018 Oct 31;8(4):297-298. Epub 2018 Oct 31.

Department of Dermatology, University Hospital Heidelberg, Ruprecht Karls University Heidelberg, Germany.

View Article
October 2018

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.

Cost Eff Resour Alloc 2018 16;16:56. Epub 2018 Nov 16.

4School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Objective: To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland.

Methods: In this semi-Markov model, subcutaneous (SC) secukinumab was compared with SC treatments etanercept and its biosimilar, certolizumab pegol, adalimumab and its biosimilar, golimumab, ustekinumab, intravenous (IV) treatment infliximab, as well as oral non-biologic apremilast. Patients without prior exposure (naïve) to biologics and without moderate to severe psoriasis were considered for secukinumab 150 mg group. Read More

View Article
November 2018

Corrigendum to "Psoriatic arthritis disease activity during pregnancy and the first-year postpartum" [Semin. Arthritis Rheum. 46 (6) (2017) 740-745].

Semin Arthritis Rheum 2018 Nov 23. Epub 2018 Nov 23.

Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Psoriatic Arthritis Program, Center for Prognostic Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article
November 2018
1 Read

Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence.

J Dermatol 2018 Nov 26. Epub 2018 Nov 26.

Faculty of Medicine of ABC, Sao Paulo, Brazil.

Interest has increased in comorbidities associated with psoriasis and their effects on health-related quality of life (HRQoL). This study aimed to evaluate the prevalence of metabolic syndrome (MetS) and psoriatic arthritis (PsA) and to investigate HRQoL and the prevalence of hypertension, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia. In a cross-sectional design, patients diagnosed with plaque psoriasis answered an interview and standardized questionnaires (Dermatology Life Quality Index questionnaire [DLQI], 36-Item Short Form Health Survey [SF-36] and EuroQol Five-Dimension Questionnaire Three-Level version [EQ-5D-3L]). Read More

View Article
November 2018
5 Reads

Persistence with biological drugs in patients treated in rheumatology practices in Germany.

Rheumatol Int 2018 Nov 24. Epub 2018 Nov 24.

Epidemiology, IQVIA, Commercial GmbH & Co OHG, Unterschweinstiege 2-14, 60549, Frankfurt am Main, Germany.

The goal of this study was to investigate the persistence with biological drugs in patients treated in rheumatology practices in Germany. This study included patients diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PA), or ankylosing spondylitis (AS) who received a first prescription of biological drugs between 2008 and 2016 (index date) in 21 rheumatology practices in Germany (n = 4925; Disease Analyzer database). The main outcome measure was the rate of persistence within 5 years of the index date. Read More

View Article
November 2018
1 Read

AS2762900-00, a potent anti-human IL-23 receptor monoclonal antibody, prevents epidermal hyperplasia in a psoriatic human skin xenograft model.

Eur J Pharmacol 2018 Nov 22;843:190-198. Epub 2018 Nov 22.

Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.

Interleukin (IL)-23 is thought to be critical in the pathogenesis of psoriasis, and anti-IL-23 monoclonal antibodies (mAbs) have been approved for the treatment of psoriasis. We speculated that an anti-IL-23 receptor mAb might have greater efficacy than an anti-IL-23 mAb in the treatment of local inflamed lesions with high IL-23 levels. We previously generated an anti-human IL-23 receptor mAb, AS2762900-00, which potently blocked IL-23-induced cell proliferation, regardless of the concentration of IL-23. Read More

View Article
November 2018
2 Reads

Treatment of end stage temporomandibular joint disorder using a temporomandibular joint total prosthesis: The Slovenian experience.

J Craniomaxillofac Surg 2018 Nov 7. Epub 2018 Nov 7.

Department for Oral and Maxillofacial Surgery, (Head: Assoc. Prof. Andrej Kansky), University Medical Centre Ljubljana, Slovenia.

Purpose: The aim of this study was to analyse treatment results after alloplastic temporomandibular joint replacement surgery.

Materials And Methods: Twelve patients who met the inclusion criteria underwent operation between the years 2012 and 2016 at the Department of Maxillofacial and Oral Surgery of the University Medical Centre Ljubljana, Slovenia. Seven patients had posttraumatic sequelae, 4 osteoarthritis and 1 psoriatic arthritis. Read More

View Article
November 2018
2 Reads

Investigation of Psoriasis Susceptibility Loci in Psoriatic Arthritis and a Generalized Pustular Psoriasis Cohort.

J Investig Dermatol Symp Proc 2018 Dec;19(2):S83-S85

Department of Dermatology, Huashan Hospital, Fudan University, Huashan Hospital, Shanghai, People's Republic of China. Electronic address:

Psoriasis is a common skin disease affecting 1-3% of the population (Gelfand et al., 2005; Ferrándiz et al., 2001). Read More

View Article
December 2018
1 Read